Historically, most planning for an emergency response to terrorism has focused on overt attacks such as bombings and attacks using chemicals. Chemical events are also likely to be overt because inhalation or skin/mucous membrane absorption of chemicals produces effects that are usually immediate and obvious. For obvious reasons, explosive and chemical attacks elicit an immediate response by law enforcement, fire and Emergency Medical Services personnel. In comparison to chemicals and explosives, the impact of biologic agents is more likely to be covert and delayed. As the recent anthrax events demonstrated, biologic agents do not have an immediate impact due to the interval between exposure and the onset of illness (the incubation period) (1). Consequently, the most likely responders to future biologic attacks will be family physicians and other primary health care providers. For example, after an intentional, covert release of Variola virus, some infected patients would arrive at their doctors' offices and local emergency rooms 1–2 weeks later. Other infected people may have traveled, and they would probably show up at emergency rooms distant from their homes. Their symptoms would appear at first to be an ordinary viral infection, including fever, back pain, headache, and nausea. As the disease progressed, many physicians would not recognize the characteristic early stage papular rash of smallpox.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Centers for Disease Control and Prevention. Biological and Chemical Terrorism: Strategic Plan for Preparedness and Response. Recommendations of the CDC Strategic Planning Workgroup. Morbidity and Mortality Weekly Report, 49(RR04):1–14, April 21, 2000.
Franz, D, Jahrling, PB, Friedlander, AM, et al. Clinical Recognition and Management of Patients Exposed to Biological Warfare Agents. Journal of the American Medical Association, 278(5):399–411, 1997.
Centers for Disease Control and Prevention. Recognition of Illness Associated with the Intentional Release of a Biologic Agent. Morbidity and Mortality Weekly Report, 50(41):893–897, 2001.
Inglesby, TV, O’Toole, T, Henderson, DA. Anthrax as a Biological Weapon, 2002. Updated Recommendations for Management. JAMA, 287(17):2236–2252, 2002.
Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a Biological Weapon. Medical and Public Health Management. JAMA, 281(18):1735–1745, 1999. Also available at http://www.bt.cdc.gov (last accessed 4/15/06).
Zilinskas, RA. Iraq’s Biological Weapons: The Past as Future? JAMA, 278(5):418–424, 1997.
Centers for Disease Control and Prevention. Update: Investigation of Bioterrorism-Related Anthrax and Interim Guidelines for Clinical Evaluation of Persons with Possible Anthrax. Morbidity and Mortality Weekly Report, 50(43):941–948, 2001.
Peters, CJ, Hartley, DM. Anthrax Inhalation and Lethal Human Infection. Lancet, 359:710–711, 2002.
Jernigan, JA, Stephens, DS, Ashford, DA, et al. Bioterrorism-Related Inhalational Anthrax: The First 10 Cases Reported in the United States. Emerging Infectious Disease, 7(6):933–944, 2001.
Centers for Disease Control and Prevention. Notice to readers: Considerations for Distinguishing Influenza-Like Illness from Inhalational Anthrax. Morbidity and Mortality Weekly Report, 50(44):984–6, 2001.
Centers for Disease Control and Prevention Update: Investigation of Bioterrorism-Related Anthrax and Interim Guidelines for Exposure Management and Antimicrobial Therapy, October 2001. Morbidity and Mortality Weekly Report, 50(42):909–919, 2001.
Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. The New England Journal of Medicine, 341:815–26, 1999.
Centers for Disease Control and Prevention. Use of Anthrax Vaccine in the United States. MMWR, 49(RR-15):1–20, 2000.
Anthrax. Centers for Disease Control and Prevention, National Immunization Program. Epidemiology and Prevention of Vaccine-Preventable Illnesses. Anthrax, Chapter 20:307–322. The Pink Book. Updated Eighth Edition, 2005. http://www.cdc.gov/nip/publications/pink/anthrax.pdf (last accessed 4/07/07).
Centers for Disease Control and Prevention. Surveillance for Adverse Events Associated with Anthrax Vaccination–US Department of Defense, 1998–2000. MMWR, 49(16):341–345, 2000.
Centers for Disease Control and Prevention. Notice to Readers: Status of U.S. Department of Defense Preliminary Evaluation of the Association of Anthrax Vaccination and Congenital Anomalies. MMWR, 51(6):127, 2002.
Centers for Disease Control and Prevention. Notice to Readers: Interim Guidelines for Investigation of and Response to Bacillus Anthracis Exposures. Morbidity and Mortality Weekly Report, 50(44):987–90, 2001.
Centers for Disease Control and Prevention. Notice to Readers: Updated Recommendations for Antimicrobial Prophylaxis Among Asymptomatic Pregnant Women After Exposure to Bacillus Anthracis. Morbidity and Mortality Weekly Report, 50(43):960, 2001.
Bell, DM, Kozarsky, PE, Stephens, DS. Conference Summary. Clinical Issues in the Prophylaxis, Diagnosis and Treatment of Anthrax. Emerging Infectious Disease, 8(2):222–225, 2002.
Shephard CW, Sorano-Gabarro, M, Zell, ER, et al. Antimicrobial Postexposure Prophylaxis for Anthrax: Adverse Events and Adherence. Emerging Infectious Disease, 8(10):1124–1137, 2002.
Centers for Disease Control and Prevention. Notice to Readers: Use of Anthrax Vaccine in Response to Terrorism: Supplemental Recommendations of the Advisory Committee on Immunization Practices. MMWR, 51(45), 2002.
Centers for Disease Control and Prevention. Prevention of Plague: Recommendations of the Advisory Committee on Immunization Practices. MMWR, 45(RR-14):1–15, 1996.
Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a Biological Weapon: Medical and Public Health Management. JAMA, 283(17):2281–2290, 2000. Also available at http://www.bt.cdc.gov (last accessed 4–15–06).
Henning KJ, Layton M. Bioterrorism. In APIC Text of Infection Control and Epidemiology. Association of Professionals in Infection Control and Epidemiology Inc. Washington, DC: Chapter 124:1–11, 2000.
Centers for Disease Control and Prevention, National Immunization Program. Epidemiology and Prevention of Vaccine-Preventable Illnesses. Chapter 19, Smallpox: 281–306, The Pink Book. Updated Eighth Edition, 2005, http://www.cdc.gov/nip/publications/pink/smallpox.pdf.
Henderson DA, Inglesby TV, Bartlett JG, et al. Smallpox as a Biological Weapon: Medical and Public Health Management. JAMA, 281:2127–2137, 1999. Also available at http://www.bt.cdc.gov (last accessed 4/15/06).
Thorne, CD, Hirshon, JM, Himes, CD, McDiarmid, MA. Emergency Medicine Tools to Manage Smallpox (Vaccinia) Vaccination Complications: Clinical Practice Guideline and Policies and Procedures. Annals of Emergency Medicine, 42(5):665–681, 2003.
US Army Medical Research Institute of Infectious Diseases. Medical Management of Biological Casualties Handbook. Fort Detrick, Frederick, Maryland, Fifth Edition, August 2004.
Centers for Disease Control and Prevention. Update: Adverse Events Following Civilian Smallpox Vaccination–United States 2003, MMWR, 53(5):106–107, 2004.
Centers for Disease Control and Prevention. Update: Adverse Events Following Smallpox Vaccination–United States, 2003. MMWR, 52(13):278–282, 2003.
Centers for Disease Control and Prevention. Smallpox Fact Sheet, Information for Clinicians, Smallpox Vaccination Method. http://www.bt.cdc.gov/agent/smallpox/vaccination/pdf/vaccination-method.pdf. (last accessed 4–08–07).
Wharton, M, Strikas, RA, Harpaz, F, et al. Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program. Supplemental Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR, 52(RR-7), 2003.
Benin, AL, Dembry, L, Shapiro, ED, Holmboe, ES. Reasons Physicians Accepted or Declined Smallpox Vaccine, February Through April, 2003. Journal of General Internal Medicine, 19:85–89, 2004.
Millock, PJ. Legal Implications of the Smallpox Vaccination Program. Journal of Public Health Management and Practice, 9(5):411–417, 2003.
United States Department of Health and Human Services. Health Resources and Services Administration, Smallpox Vaccine Injury Compensation Program: Administrative Implement, 42 CFR Part 102, Federal Register/Vol. 68, No. 241/Tuesday, December 16, 2003/Rules and Regulations, http://publichealthlaw.law.lsu.edu/blaw/hhs/42-crf-102.pdf, also at http://www.hrsa.gov/Smallpoxinjury/frn121603.htm.
Arnon SS, Schechter R, Inglesby TV, et al. Botulinum Toxin as a Biological Weapon: Medical and Public Health Management. JAMA, 285:1059–1070, 2001. Also available at http://www.bt.cdc.gov (last accessed 11/3/2001).
American Society for Microbiology. Sentinel Laboratory Guidelines for Suspected Agents Of Bioterrorism. Botulinum Toxin. http://www.asm.org/ASM/files/LEFTMARGINHEADERLIST/downloadfilename/0000000522/BotulismFinalVersion73003.pdf, last accessed 4–15–06.
Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases. Botulism in the United States 1899–1966. Handbook for Epidemiologists, Clinicians and Laboratory Workers, Atlanta, Georgia 1998.
Centers for Disease Control and Prevention, National Center for Infectious Diseases, Division of Bacterial and Mycotic Diseases. Surveillance for Botulism. Summary of 2001 Data. http://www.cdc.gov/ncidod/dbmd/diseaseinfo/files/BotCSTE2001.pdf. Last accessed 4/15/06.
Centers for Disease Control and Prevention. Tularemia–United States, 1990–2000. MMWR, 51(9):181–185, 2002.
Centers for Disease Control and Prevention, American Society of Microbiology and Association of Public Health Laboratories. Basic Protocols for Level A Laboratories for Presumptive Identification of Francisella Tularensis. December, 2001, http://www.asm.org/ASM/files/LEFTMARGINHEADERLIST/DOWNLOADFILENAME/0000000525/tularemiaprotocol%5B1%5D.pdf, last accessed 4/15/06.
McCoy, GW, Chapin, CW. V. Bacterium Tularense, The Cause of a Plague-Like Disease of Rodents. Public Health Bulletin, 53:17–23, 1912.
Dennis, DT, Inglesby, TV, Henderson, DA, et al. Tularemia as a Biological Weapon: Medical and Public Health Management. JAMA, 285(21):2763–2773, 2001. Also available at http://www.bt.cdc.gov (last accessed 4/15/06).
Alibek, K. Biohazard. New Yorik, NY. Random House, 1999:29–38.
Kauffman, AF, Meltzer, MI, and Schmid, GP. The Economic Impact of a Bioterrorist Attack: Are Prevention and Post-Attack Intervention Programs Justifiable? Emerging Infectious Disease, 2:83–94, 1997.
Alluisi, EA, Beisel, WR, Bartonelli, PJ, Coates, GD. Behavioral Effectos of Tularemia and Sandfly Fever in Man. Journal of Infectious Disease, 128:710–717, 1973.
Centers for Disease Control and Prevention. Viral Hemorrhagic Fevers: Fact Sheets. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/vhf.htm. Last accessed 4/15/06.
Jahrling, PB. Viral Hemorrhagic Fevers. In Sidell, FR, Takafuji, ET, Franz, DR (Eds.). Medical Aspects of Chemical and Biological Warfare. Chapter 29:591–602 Borden Institute, Walter Reed Army Medical Center. Washington DC 1997. http://www.bordeninstitute.army.mil/published_volumes/chemBio/Ch29.pdf, last accessed 4/15/06.
Centers for Disease Control and Prevention. Arena Virus Fact Sheets. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Arenavirus_Fact_Sheet.pdf. Last accessed 4/15/06.
Centers for Disease Control and Prevention. Lassa Fever Fact Sheet. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Lassa_Fever_Fact_Sheet.pdf. Last accessed 4/15/06.
Centers for Disease Control and Prevention. Rift Valley Fever Fact Sheet. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Rift_Valley_Fever_Fact_Sheet.pdf. Last accessed 4/15/06.
Centers for Disease Control and Prevention. Hantavirus Pulmonary Syndrome–United States: Updated Recommendations for Risk Reduction Morbidity and Mortality Weekly Report, 51(RR-9), July 26, 2002.
Centers for Disease Control and Prevention. http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Filovirus_Fact_Sheet.pdf. Last accessed 4/15/06.
Centers for Disease Control and Prevention. Interim guidance for Managing Patients with Suspected Viral Hemorrhagic Fever in U.S. Hospitals. May 19, 2005. http://www.cdc.gov/ncidod/dhqp/bp_vhf_interimGuidance.html Last accessed 4/15/06.
Bronze, MS, Huycke, MM, Machado, JL, Voskuhl, GW, Greenfield, RA. Viral Agents as Biological Weapons and Agents of Bioterrorism. American Journal of Medical Science, 323(6):316–325, 2002.
Price, ME, Fisher-Hoch, SP, Craven, RB, McCormick, JB. A Prospective Study of Maternal and Fetal Outcome in Acute Lassa Fever Infection During Pregnancy. British Medical Journal, 297(6648):584–587, 1988.
Whitehouse, CA. Crimean–Congo Hemorrhagic Fever. Antiviral Research, 64(3):145–160, 2004.
Ergonul, O, Celikbas, A, Dokuzoguz, B, Eren, S, Baykam, N, Esener, H. Characteristics of Patients with Crimean–Congo Hemorrhagic Fever in a Recent Outbreak in Turkey and Impact of Oral Ribavirin Therapy. Clinical Infectious Diseases, 39(2):284–287, 2004.
Mardani, M, Jahromi, MK, Naieni, KH, Zeinali, M. The Efficacy of Oral Ribavirin in the Treatment of Crimean–Congo Hemorrhagic Fever in Iran. Clinical Infectious Diseases, 36(12):1613–1618, 2003.
Sidwell, RW, Smee, DF. Viruses of the Bunya- and Togaviridae Families: Potential as Bioterrorism Agents and Means of Control. Antiviral Research, 57(1–2):101–111, 2003.
Garner, JS. Guideline for Isolation Precautions in Hospitals. Centers for Disease Control and Prevention, Division of Healthcare Quality Promotion http://www.cdc.gov/ncidod/dhqp/gl_isolation.html. Last accessed 4/15/06.
Centers for Disease Control and Prevention and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. Fourth Edition, Washington DC, 1999. http://www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm (last accessed 4/15/06).
Centers for Disease Control and Prevention. Guidelines for Environmental Infection Control in Healthcare Facilities. Atlanta, Ga, 2003. http://www.cdc.gov/ncidod/dhqp/gl_environinfection.html. (last accessed 4/15/06).
Hart, MK. Vaccine Research Efforts for Filoviruses. International Journal for Parasitology, 33(5–6):583–595, 2003.
Custer, DM, Thompson, E, Schmaljohn, CS, Ksiazek, TG, Hooper, JW. Active and Passive Vaccination against Hantavirus Pulmonary Syndrome with Andes Virus M Genome Segment-Based DNA Vaccine. Journal of Virology, 77(18):9894–9905, 2003.
Centers for Disease Control and Prevention. Dengue Fever home page. http://www.cdc.gov/ncidod/dvbid/dengue/index.htm. Last accessed 4/15/06.
Khan, AS, Swerdlow, DL, Juranek, DD. Precautions Against Biological and Chemical Terrorism Directed at Food and Water Supplies. Public Health Reports, 116(1):3–14, 2001.
Meinhardt, PL. Water and Bioterrorism: Preparing for the Potential Threat to U.S. Water Supplies and Public Health. Annual Review Public Health, 26:213–37, 2005.
Rights and permissions
Copyright information
© 2008 Springer
About this chapter
Cite this chapter
(2008). Biological Terrorism. In: Biological, Chemical, and Radiological Terrorism. Springer, New York, NY. https://doi.org/10.1007/978-0-387-47232-4_2
Download citation
DOI: https://doi.org/10.1007/978-0-387-47232-4_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-47231-7
Online ISBN: 978-0-387-47232-4
eBook Packages: MedicineMedicine (R0)